Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and NDRG1 genes

Authors: Osman Salis, Ali Okuyucu, Abdulkerim Bedir, Ufuk Gör, Canan Kulcu, Eser Yenen, Nermin Kılıç

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Metastasis occurs due to migration of the cells from primary tumor toward other tissues by gaining invasive properties. Since metastatic invasion shows a strong resistance against conventional cancer treatments, the studies on this issue have been focused. Within this context, inhibition of migration and determination of the relationships at the gene level will contribute to treatment of metastatic cancer cases. We have aimed to demonstrate the impact of TGF-β1 and fluvastatin on human breast cancer (MCF-7) and human hepatocellular carcinoma (Hep3B) cell cultures via Real-Time Cell Analyzer (RTCA) and to test the expression levels of some genes (NDRG1, SGK1, TWIST1, AMPKA2) and to compare their gene expression levels according to RTCA results. Both of cell series were applied TGF-β1 and combinations of TGF-β1/fluvastatin. Primer and probes were synthesized using Universal Probe Library (UPL, Roche) software, and expression levels of genes were tested via qPCR using the device LightCycler 480 II (Roche). Consequently, fluvastatin dose-dependently inhibited migration induced by TGF-β1 in both groups. This inhibition was accompanied by low level of SGK1 messenger RNA (mRNA) and high levels of NDRG1 and AMPKA2 mRNA. Thus, we conclude that fluvastatin plays an important role in reducing resistance to chemotherapeutics and preventing metastasis.
Literature
1.
Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8:629–42.CrossRefPubMed
2.
3.
4.
5.
Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004;104:2967–75.CrossRefPubMed
6.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMed
7.
Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.CrossRefPubMed
8.
Ikushima H, Miyazono K. TGFb signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.CrossRefPubMed
9.
10.
Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25(3):435–57.CrossRefPubMed
11.
12.
de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst. 2000;92(17):1388–402.CrossRefPubMed
13.
Derynck R, Akhurst RJ. Balmain A TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29(2):117–29.CrossRefPubMed
14.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.CrossRefPubMedPubMedCentral
15.
Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition ofbreast tumor heterogeneity. Cancer Cell. 2007;11(3):259–73.CrossRefPubMed
16.
Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J, et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2010;14:1180–93.PubMed
17.
Barbie T-H, Sandra O, Karlan BY, Andrew J. Li Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol. 2010;119:549–56.CrossRef
18.
Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508–19.CrossRefPubMed
19.
Cohen AW, Schubert W, Brasaemle DL, Scherer PE, Lisanti MP. Caveolin-1 expression is essential for proper nonshivering thermogenesis in brown adipose tissue. Diabetes. 2005;54(3):679–86.CrossRefPubMed
20.
21.
Lang F, Shumilina E. Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1. FASEB J. 2013;27(1):3–12.CrossRefPubMed
22.
Lang F, Artunc F, Vallon V. The physiological impact of the serum and glucocorticoidinducible kinase SGK1. Curr Opin Nephrol Hypertens. 2009;18:439–48.CrossRefPubMedPubMedCentral
23.
Salis O, Bedir A, Gulten S, Okuyucu A, Kulcu C, Alacam H. Cytotoxic Effect of Fluvastatin on MCF-7 Cells Possibly Through a Reduction of the mRNA Expression Levels of SGK1 and CAV1. Cancer Biother Radiopharm. 2014;29(9):368–75.CrossRefPubMed
24.
Thomas P, Ellen TP, Ke Q, Zhang P. () NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis. 2008;29:2–8.
25.
Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000;60:749–55.PubMed
26.
Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, et al. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003;63:1731–6.PubMed
27.
Sun B, Chu D, Li W, Chu X, Li Y, Wei D, et al. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol. 2009;94:213–9.CrossRefPubMed
28.
Chua MS, Sun H, Cheung ST, Mason V, Higgins J, Ross DT, et al. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol. 2006;20:76–83.CrossRefPubMed
29.
30.
Salis O, Bedir A, Kilinc V, Alacam H, Gulten S, Okuyucu A. The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells. Cancer Biomark. 2014;14(6):419–26.PubMed
31.
Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, et al. ”AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem. 2004;279:47898–905.CrossRefPubMed
32.
Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277:1–10.
33.
Chen Y, Doebber T, Hirshman MF, Goodyear LJ, Fenyk-Melody J, Fujii N, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.CrossRefPubMedPubMedCentral
34.
Mironchik Y, Winnard Jr PT, Vesuna F, Kato Y, Wildes F, Pathak AP, et al. Twist over expression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 2005;65(23):10801–9.CrossRefPubMed
35.
36.
Schoenebeck B, Bader XR, Schmitz B, Lubbert H, Stichel C. Sgk1, a cell survival response in neurodegenerative diseases. Mol Cell Neurosci. 2005;30(2):249–64.CrossRefPubMed
37.
Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006;86:1151–78.CrossRefPubMed
38.
Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, Uemura Y, et al. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res. 2009;69:5321–30.CrossRefPubMed
39.
Hoppe S, Bierhoff H, Cado I, Weber A, Tiebe M, Grummt I, et al. AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. Proc Natl Acad Sci U S A. 2009;106:17781–6.CrossRefPubMedPubMedCentral
40.
Hardie DG, Alessi DR. LKB1 and AMPK and the cancer-metabolismlink-ten years after. BMC Biol. 2013;15:11–36.
Metadata
Title
Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and NDRG1 genes
Authors
Osman Salis
Ali Okuyucu
Abdulkerim Bedir
Ufuk Gör
Canan Kulcu
Eser Yenen
Nermin Kılıç
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4119-2

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma

Original Article

Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium

Original Article

miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression

Original Article

The potential role of the NEK6, AURKA, AURKB, and PAK1 genes in adenomatous colorectal polyps and colorectal adenocarcinoma

Original Article

Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer

Original Article

Plasma miR-940 may serve as a novel biomarker for gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits